Sign in
Enrolling by invitationNo phase

Corneal Endothelium in Active Thyroid Eye Disease Treated With Local Steroid Injection

Key facts

Who runs it
Assiut University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Enrolling by invitation
People taking part
38 people, planned
Started
1 Mar 2026
Expected to end
Mar 2027
Type of study
Observational
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • clinical diagnosis of thyroid eye disease
  • patients above age of 18
  • TED duration less than 18 months\& clinical activity score equal or more than 3

Who cannot take part

  • 1. History of ocular trauma or surgery. 2. Topical ocular medication use, previous ophthalmic intervention, contact lens wear 3. Ophthalmic diseases, such as corneal disease, glaucoma, or any ocular disease that might affect the corneal endothelium 4. uncontrolled hypertension, diabetes mellitus, or systemic diseases other than autoimmune thyroid condition which may have an impact on the corneal endothelium 5. Patients in the fibrotic phase of thyroid eye disease. 6. Contraindications to steroid therapy

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

TED is an autoimmune disease that may cause stress to the corneal endothelium which may differ by the degree of inflammation.

Read full original descriptionShow less

Previous studies found that corneal endothelial cell morphology significantly changed in active TED patients compared with inactive TED patients.

The mechanism underlying the morphological changes in corneal endothelium of active TED is still unclear. One possible explanation is increased ocular surface inflammation, particularly during the active phase. Huang et al. reported elevated levels of tear inflammatory cytokines, including interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α in active TED compared to inactive TED and controls. Villani et al. demonstrated a higher number of activated corneal keratocytes in active TED, indicating more pronounced corneal inflammation.

Local injection of steroid has been utilized in active TED with promising results. the local steroid injection has the advantage of delivering the steroid directly to the site of the pathology maximizing its concentration and effect and minimizing the systemic side effects of steroid.

All Previous reports about corneal endothelial changes in TED were of cross-sectional design and lacks longitudinal follow-up. To the best of authors, knowledge, this is the first study to evaluate changes in corneal endothelial morphology in active TED patients following local steroid treatment.

The group in the trial

  • TED

    active TED

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Corneal Endothelial Morphology in Active Thyroid Eye Disease Treated With Local Betamethasone Injection.
Record updated
17 November 2026